Company overview
Basic information
Company name
TEOFARMA, UAB
Company code
135815688
VAT code
LT358156811
Registered address
Kaunas, Laisvės al. 81A, LT-44297
Registration date
2001-10-01
Company age: 25 y.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Website
None
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Private Limited Liability Company
NACE activity
Business and other management consultancy activities
Ownership form
Private without foreign capital
UAB "TEOFARMA"
Company code: 135815688
Address: Kaunas, Laisvės al. 81A, LT-44297
VAT code: LT358156811
Description
This description was generated by artificial intelligence.
TEOFARMA, UAB (company code 135815688) is an operational private limited liability company registered on 1 October 2001. It is classified as a private enterprise within the national private non-financial companies sector and is owned through private Lithuanian ownership, with more than 50% of authorised capital held by Lithuanian natural and legal persons and no foreign investor capital. The company is governed by a CEO only and is listed as a micro-sized business. Its registered address is Laisves al. 81A, Kaunas, Kauno m. municipality, Kauno county. The company’s main activity is N.70.20.00, Business and other management consultancy activities. Financially, TEOFARMA recorded revenue of EUR 23.8K in 2025, up 68.8% year on year, and EUR 4.8K in net profit, with a profit margin of 20.1%. Revenue also increased by 47.0% over two years. Equity remained negative at EUR -37.9K, while liabilities stood at EUR 43.4K and total assets at EUR 5.5K at the end of 2025. Staffing has remained small: the company averaged 1 employee in 2023, 2024 and 2025, and so far in 2026 it has averaged 2 employees.
Download a detailed company report
Make confident decisions with all the information about TEOFARMA, UAB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.